Issuer identity and financial position
Cardiol Therapeutics Inc. is a clinical-stage developer of cannabidiol-based therapies for inflammatory heart disease. Its common equity trades as Nasdaq: CRDL and TSX: CRDL. Those are two listings of the same issuer, not two companies, and neither row should inherit a separate valuation.
The June 30 financial statements and MD&A report in Canadian dollars. Cash was C$26.081 million. Accounts payable and accrued liabilities were C$3.748 million and lease liabilities were C$0.107 million, leaving C$22.226 million after those two recorded operating claims. A separate C$1.474 million derivative warrant liability should not be subtracted as cash debt while the same equity-settled warrants are also treated as dilution.
First-half operating cash outflow, capital spending and lease principal totaled C$11.975 million, or about C$1.996 million per month. June cash therefore represented roughly 13.1 months of that backward-looking pace before subsequent warrant proceeds, trial expansion and future program spending. Management’s projected runway into the first quarter of 2028 remains a company forecast, not independently proven funding capacity.
Capital and development requirements
June issued shares were 115.885 million. Options, performance and restricted units, and warrants added 19.771 million potential shares, a 17.1% overhang versus June basic shares and a 135.656 million fully diluted reference before instrument-specific vesting and exercise treatment. The September prospectus reported 120.660 million issued shares, 4.776 million above June. A September warrant-exercise announcement cited more than US$7 million of proceeds, but those proceeds are cumulative and overlap June exercises; they cannot simply be added to June cash.
The prospectus estimated at least C$27 million for remaining MAVERIC, NDA and CRD-38 development stages, excluding quarterly cash G&A of C$2.5–3.0 million. One year of that G&A would lift the combined planning figure to about C$37–39 million, before independent U.S. commercialization spending estimated at C$40–50 million absent a partner.
A September 23 update increased planned MAVERIC enrollment from 110 to 150 and moved topline guidance to mid-2027. Fewer blinded recurrences do not identify which arm benefits and are not efficacy proof. The amended protocol, event assumptions and expanded-trial budget remain necessary before assigning a success probability or clinical rNPV.
CIN conclusion
Cardiol has a legitimate cannabinoid-development program and meaningful cash, but trial expansion, post-October warrant reconciliation, future financing and unproven commercialization economics prevent a qualified equity valuation. This is a concise initial company review, not a completed clinical rNPV or valuation underwrite. CIN therefore assigns NotRated with no current rating, price target, reference quote or upside.